VEGFA and colorectal carcinoma: Specifically, we propose that (i) clinical validation of their plasma levels can demonstrate superior diagnostic accuracy compared to traditional markers, (ii) molecular docking analyses provide mechanistic insight into how miR-155 regulates VEGF-driven pathways relevant to CRC progression, and (iii) integration of these biomarkers with clinical risk factors through AI-based modeling enhances predictive performance.